Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Suzanne Eccles; Eric Aboagye; Simak Ali; Annie Anderson; Jo Armes; Fedor Berditchevski; Jeremy Blaydes; Keith Brennan; Nicola J. Brown; Helen Bryant; Nigel Bundred; Joy Burchell; Anna Campbell; Jason Carroll; Robert Clarke; Charlotte Coles; Gary Cook; Angela Cox; Nicola Curtin; Lodewijk Dekker; Isabel dos Santos Silva; Stephen Duffy; Douglas Easton; Diana Eccles; Dylan Edwards; Joanne Edwards; D. Evans; Deborah Fenlon; James Flanagan; Claire Foster; William Gallagher; Montserrat Garcia-Closas; Julia Gee; Andy Gescher; Vicky Goh; Ashley Groves; Amanda Harvey; Michelle Harvie; Bryan Hennessy; Stephen Hiscox; Ingunn Holen; Sacha Howell; Anthony Howell; Gill Hubbard; Nick Hulbert-Williams; Myra Hunter; Bharat Jasani; Louise Jones; Timothy Key; Cliona Kirwan; Anthony Kong; Ian Kunkler; Simon Langdon; Martin Leach; David Mann; John Marshall; Lesley Martin; Stewart Martin; Jennifer Macdougall; David Miles; William Miller; Joanna Morris; Sue Moss; Paul Mullan; Rachel Natrajan; James O'Connor; Rosemary O'Connor; Carlo Palmieri; Paul Pharoah; Emad Rakha; Elizabeth Reed; Simon Robinson; Erik Sahai; John Saxton; Peter Schmid; Matthew Smalley; Valerie Speirs; Robert Stein; John Stingl; Charles Streuli; Andrew Tutt; Galina Velikova; Rosemary Walker; Christine Watson; Kaye Williams; Leonie Young; Alastair M. Thompson

doi:10.1186/bcr3493

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Suzanne Eccles, Eric Aboagye, Simak Ali, Annie Anderson, Jo Armes, Fedor Berditchevski, Jeremy Blaydes, Keith Brennan, Nicola J. Brown, Helen Bryant, Nigel Bundred, Joy Burchell, Anna Campbell, Jason Carroll, Robert Clarke, Charlotte Coles, Gary Cook, Angela Cox, Nicola Curtin, Lodewijk DekkerIsabel dos Santos Silva, Stephen Duffy, Douglas Easton, Diana Eccles, Dylan Edwards, Joanne Edwards, D. Evans, Deborah Fenlon, James Flanagan, Claire Foster, William Gallagher, Montserrat Garcia-Closas, Julia Gee, Andy Gescher, Vicky Goh, Ashley Groves, Amanda Harvey, Michelle Harvie, Bryan Hennessy, Stephen Hiscox, Ingunn Holen, Sacha Howell, Anthony Howell, Gill Hubbard, Nick Hulbert-Williams, Myra Hunter, Bharat Jasani, Louise Jones, Timothy Key, Cliona Kirwan, Anthony Kong, Ian Kunkler, Simon Langdon, Martin Leach, David Mann, John Marshall, Lesley Martin, Stewart Martin, Jennifer Macdougall, David Miles, William Miller, Joanna Morris, Sue Moss, Paul Mullan, Rachel Natrajan, James O'Connor, Rosemary O'Connor, Carlo Palmieri, Paul Pharoah, Emad Rakha, Elizabeth Reed, Simon Robinson, Erik Sahai, John Saxton, Peter Schmid, Matthew Smalley, Valerie Speirs, Robert Stein, John Stingl, Charles Streuli, Andrew Tutt, Galina Velikova, Rosemary Walker, Christine Watson, Kaye Williams, Leonie Young, Alastair M. Thompson

Sport Exercise and Rehabilitation Department

Research output: Contribution to journal › Article › peer-review

325 Citations (Scopus)

14 Downloads (Pure)

Abstract

INTRODUCTION Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. METHODS More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer 'stem' cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account. RESULTS The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working. CONCLUSIONS With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

Original language	English
Pages (from-to)	R92
Journal	Breast cancer research : BCR
Volume	15
Issue number	5
DOIs	https://doi.org/10.1186/bcr3493
Publication status	Published - 1 Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/bcr3493

Saxton J research gaps cancerFinal published version, 1.05 MB

Cite this

Eccles, S., Aboagye, E., Ali, S., Anderson, A., Armes, J., Berditchevski, F., Blaydes, J., Brennan, K., Brown, N. J., Bryant, H., Bundred, N., Burchell, J., Campbell, A., Carroll, J., Clarke, R., Coles, C., Cook, G., Cox, A., Curtin, N., ... Thompson, A. M. (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast cancer research : BCR, 15(5), R92. https://doi.org/10.1186/bcr3493

@article{47fda4369e114b7a91335201e88e07fd,

title = "Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer",

abstract = "INTRODUCTION Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. METHODS More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer 'stem' cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account. RESULTS The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working. CONCLUSIONS With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.",

author = "Suzanne Eccles and Eric Aboagye and Simak Ali and Annie Anderson and Jo Armes and Fedor Berditchevski and Jeremy Blaydes and Keith Brennan and Brown, {Nicola J.} and Helen Bryant and Nigel Bundred and Joy Burchell and Anna Campbell and Jason Carroll and Robert Clarke and Charlotte Coles and Gary Cook and Angela Cox and Nicola Curtin and Lodewijk Dekker and Silva, {Isabel dos Santos} and Stephen Duffy and Douglas Easton and Diana Eccles and Dylan Edwards and Joanne Edwards and D. Evans and Deborah Fenlon and James Flanagan and Claire Foster and William Gallagher and Montserrat Garcia-Closas and Julia Gee and Andy Gescher and Vicky Goh and Ashley Groves and Amanda Harvey and Michelle Harvie and Bryan Hennessy and Stephen Hiscox and Ingunn Holen and Sacha Howell and Anthony Howell and Gill Hubbard and Nick Hulbert-Williams and Myra Hunter and Bharat Jasani and Louise Jones and Timothy Key and Cliona Kirwan and Anthony Kong and Ian Kunkler and Simon Langdon and Martin Leach and David Mann and John Marshall and Lesley Martin and Stewart Martin and Jennifer Macdougall and David Miles and William Miller and Joanna Morris and Sue Moss and Paul Mullan and Rachel Natrajan and James O'Connor and Rosemary O'Connor and Carlo Palmieri and Paul Pharoah and Emad Rakha and Elizabeth Reed and Simon Robinson and Erik Sahai and John Saxton and Peter Schmid and Matthew Smalley and Valerie Speirs and Robert Stein and John Stingl and Charles Streuli and Andrew Tutt and Galina Velikova and Rosemary Walker and Christine Watson and Kaye Williams and Leonie Young and Thompson, {Alastair M.}",

note = "Creative Commons Attribution License http://creativecommons.org/licenses/by/2.0",

year = "2013",

month = oct,

day = "1",

doi = "10.1186/bcr3493",

language = "English",

volume = "15",

pages = "R92",

journal = "Breast cancer research : BCR",

issn = "1465-542X",

publisher = "BioMed Central",

number = "5",

}

Eccles, S, Aboagye, E, Ali, S, Anderson, A, Armes, J, Berditchevski, F, Blaydes, J, Brennan, K, Brown, NJ, Bryant, H, Bundred, N, Burchell, J, Campbell, A, Carroll, J, Clarke, R, Coles, C, Cook, G, Cox, A, Curtin, N, Dekker, L, Silva, IDS, Duffy, S, Easton, D, Eccles, D, Edwards, D, Edwards, J, Evans, D, Fenlon, D, Flanagan, J, Foster, C, Gallagher, W, Garcia-Closas, M, Gee, J, Gescher, A, Goh, V, Groves, A, Harvey, A, Harvie, M, Hennessy, B, Hiscox, S, Holen, I, Howell, S, Howell, A, Hubbard, G, Hulbert-Williams, N, Hunter, M, Jasani, B, Jones, L, Key, T, Kirwan, C, Kong, A, Kunkler, I, Langdon, S, Leach, M, Mann, D, Marshall, J, Martin, L, Martin, S, Macdougall, J, Miles, D, Miller, W, Morris, J, Moss, S, Mullan, P, Natrajan, R, O'Connor, J, O'Connor, R, Palmieri, C, Pharoah, P, Rakha, E, Reed, E, Robinson, S, Sahai, E, Saxton, J, Schmid, P, Smalley, M, Speirs, V, Stein, R, Stingl, J, Streuli, C, Tutt, A, Velikova, G, Walker, R, Watson, C, Williams, K, Young, L & Thompson, AM 2013, 'Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer', Breast cancer research : BCR, vol. 15, no. 5, pp. R92. https://doi.org/10.1186/bcr3493

TY - JOUR

T1 - Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

AU - Eccles, Suzanne

AU - Aboagye, Eric

AU - Ali, Simak

AU - Anderson, Annie

AU - Armes, Jo

AU - Berditchevski, Fedor

AU - Blaydes, Jeremy

AU - Brennan, Keith

AU - Brown, Nicola J.

AU - Bryant, Helen

AU - Bundred, Nigel

AU - Burchell, Joy

AU - Campbell, Anna

AU - Carroll, Jason

AU - Clarke, Robert

AU - Coles, Charlotte

AU - Cook, Gary

AU - Cox, Angela

AU - Curtin, Nicola

AU - Dekker, Lodewijk

AU - Silva, Isabel dos Santos

AU - Duffy, Stephen

AU - Easton, Douglas

AU - Eccles, Diana

AU - Edwards, Dylan

AU - Edwards, Joanne

AU - Evans, D.

AU - Fenlon, Deborah

AU - Flanagan, James

AU - Foster, Claire

AU - Gallagher, William

AU - Garcia-Closas, Montserrat

AU - Gee, Julia

AU - Gescher, Andy

AU - Goh, Vicky

AU - Groves, Ashley

AU - Harvey, Amanda

AU - Harvie, Michelle

AU - Hennessy, Bryan

AU - Hiscox, Stephen

AU - Holen, Ingunn

AU - Howell, Sacha

AU - Howell, Anthony

AU - Hubbard, Gill

AU - Hulbert-Williams, Nick

AU - Hunter, Myra

AU - Jasani, Bharat

AU - Jones, Louise

AU - Key, Timothy

AU - Kirwan, Cliona

AU - Kong, Anthony

AU - Kunkler, Ian

AU - Langdon, Simon

AU - Leach, Martin

AU - Mann, David

AU - Marshall, John

AU - Martin, Lesley

AU - Martin, Stewart

AU - Macdougall, Jennifer

AU - Miles, David

AU - Miller, William

AU - Morris, Joanna

AU - Moss, Sue

AU - Mullan, Paul

AU - Natrajan, Rachel

AU - O'Connor, James

AU - O'Connor, Rosemary

AU - Palmieri, Carlo

AU - Pharoah, Paul

AU - Rakha, Emad

AU - Reed, Elizabeth

AU - Robinson, Simon

AU - Sahai, Erik

AU - Saxton, John

AU - Schmid, Peter

AU - Smalley, Matthew

AU - Speirs, Valerie

AU - Stein, Robert

AU - Stingl, John

AU - Streuli, Charles

AU - Tutt, Andrew

AU - Velikova, Galina

AU - Walker, Rosemary

AU - Watson, Christine

AU - Williams, Kaye

AU - Young, Leonie

AU - Thompson, Alastair M.

N1 - Creative Commons Attribution License http://creativecommons.org/licenses/by/2.0

PY - 2013/10/1

Y1 - 2013/10/1

N2 - INTRODUCTION Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. METHODS More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer 'stem' cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account. RESULTS The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working. CONCLUSIONS With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

AB - INTRODUCTION Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice. METHODS More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer 'stem' cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account. RESULTS The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working. CONCLUSIONS With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.

U2 - 10.1186/bcr3493

DO - 10.1186/bcr3493

M3 - Article

SN - 1465-542X

VL - 15

SP - R92

JO - Breast cancer research : BCR

JF - Breast cancer research : BCR

IS - 5

ER -

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this